Clinical guidance for choosing the right pharmacotherapy for migraine attacks

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi: 10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Laurell K, Artto V, Bendtsen L, et al. Premonitory symptoms in migraine: a cross-sectional study in 2714 persons. Cephalalgia. 2016;36(10):951–959. doi: 10.1177/0333102415620251
   PubMed Web of Science ®Google Scholar
• Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688–695. doi: 10.1212/WNL.0000000000001256
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):954–976. doi: 10.1016/S1474-4422(18)30322-3
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner L, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17. doi: 10.1186/s10194-018-0846-2
   PubMed Web of Science ®Google Scholar
• Robbins MS, Victorio MC, Bailey M, et al. Quality improvement in neurology: headache quality measurement set. Neurology. 2020;95(19):866–873. doi: 10.1212/WNL.0000000000010634
   PubMed Web of Science ®Google Scholar
• Linde M, Mellberg A, Dahlöf C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia. 2006;26(6):712–721. doi: 10.1111/j.1468-2982.2006.01097.x
   PubMed Web of Science ®Google Scholar
• Orr SL, Friedman BW, Christie SIW. Management of adults with acute migraine in emergency department: the American headache society evidence assessment of parental pharmacotherapies. Headache. 2016;56(6):911–940. doi: 10.1111/head.12835
   PubMed Web of Science ®Google Scholar
• Ailani J, Burch RC, Robbins MS, et al. Board of directors of the American headache society. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021–1039.
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A, et al. European federation of neurological societies. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–981. doi: 10.1111/j.1468-1331.2009.02748.x
   PubMed Web of Science ®Google Scholar
• Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–514. doi: 10.1038/s41582-021-00509-5
   PubMed Web of Science ®Google Scholar
• Stępień A, Kozubski W, Rożniecki JJ, et al. Migraine treatment recommendations developed by an expert group of the polish headache society, the headache section of the polish neurological society, and the polish pain society. Neurol Neurochir Pol. 2021;55(1):33–51. doi: 10.5603/PJNNS.a2021.0007
   PubMed Web of Science ®Google Scholar
• Domitrz I, Kozubski W, Boczarska-Jedynak M, et al. The Polish experts’ consensus statement: 2023 update on new therapies for migraine. Arch Med Sci. 2024;1(vol20):AMS-16153-2023–02.
   Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3–20. doi: 10.1111/head.12499
   PubMed Web of Science ®Google Scholar
• Fiebich BL, Lieb K, Hull M, et al. Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E2 in microglial cells. Neuropharmacology. 2000;39(11):2205–2213. doi: 10.1016/S0028-3908(00)00045-9
   PubMed Web of Science ®Google Scholar
• Dinner HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double – blind, single – dose, placebo – controlled parallel group study. Cephalalgia. 2005;25:776–787.
   PubMed Web of Science ®Google Scholar
• Goldstein J, Silberstein SD, Elkind AH, et al. A placebo-controlled comparison of the combination of acetaminophen, aspirin, and caffeine with sumatriptan succinate in the early treatment of migraine: results from the asset trial. Program and abstracts of the 55th Annual Scientific Meeting of the American Academy of Neurology, March 29-April 5; 2003; Honolulu, Hawaii. Abstract S22.005.
   Google Scholar
• Diener HC, de Liano G, Bussone H, et al. Placebo controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia. 2004;24(11):947–954. doi: 10.1111/j.1468-2982.2004.00783.x
   PubMed Web of Science ®Google Scholar
• Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005;64(3):463–468. doi: 10.1212/01.WNL.0000150904.28131.DD
   PubMed Web of Science ®Google Scholar
• Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia. 1995;15(6):531–535. doi: 10.1046/j.1468-2982.1995.1506531.x
   PubMed Web of Science ®Google Scholar
• Dahlof C, Bjorkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia. 1993;13(2):117–123. doi: 10.1046/j.1468-2982.1993.1302117.x
   PubMed Web of Science ®Google Scholar
• Lipton RB, Munjal S, Brand-Schieber E, et al. Efficacy, tolerability, and safety of DFN-15 (celecoxib oral solution, 25 mg/ml) in the acute treatment of episodic migraine: a randomized, double-blind, placebo-controlled study. Headache. 2020;60(1):58–70. doi: 10.1111/head.13663
   PubMed Web of Science ®Google Scholar
• Drug Approval Package: Elyxyb. [cited 2021 Mar 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212157Orig1s000TOC.cfm
   Google Scholar
• Lainez MJ, Galvan J, Heras J, et al. Crossover, double blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy.Eur. J Neurol. 2007;14(3):269–275. doi: 10.1111/j.1468-1331.2006.01594.x
   Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668. doi: 10.1016/S0140-6736(01)06711-3
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Schoenen J, et al. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004;11(10):671–677. doi: 10.1111/j.1468-1331.2004.00914.x
   PubMed Web of Science ®Google Scholar
• Diener HC, Ryan R, Sun W, et al. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol. 2004;11(2):125–134. doi: 10.1046/j.1351-5101.2003.00730.x
   PubMed Web of Science ®Google Scholar
• Lainez MJA. Clinical benefits of early triptan therapy for migraine. Cephalalgia. 2004;24(2_suppl):24–30. doi: 10.1111/j.1468-2982.2004.00895.x
   PubMedGoogle Scholar
• Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. Non-early intervention in acute migraine — ‘act when mild (AwM)’. A double-blind, placebo-controlled trial of Almotriptan. Cephalalgia. 2008;28(4):383–391. doi: 10.1111/j.1468-2982.2008.01546.x
   PubMed Web of Science ®Google Scholar
• Marcus SC, Shewale AR, Silberstein SD, et al. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020;40(7):639–649. doi: 10.1177/0333102420915167
   PubMed Web of Science ®Google Scholar
• Stark S, Spierings ELH, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache. 2000;40(7):513–520. doi: 10.1046/j.1526-4610.2000.00082.x
   PubMed Web of Science ®Google Scholar
• Edwards KR, Rosenthal BL, Farmer KU, et al. Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function. Headache. 2013;53(4):656–664. doi: 10.1111/head.12052
   PubMed Web of Science ®Google Scholar
• Leroux E, Buchanan A, Lombard L, et al. Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. 2020;37(12):4765–4796. doi: 10.1007/s12325-020-01494-9
   PubMed Web of Science ®Google Scholar
• Hall G, Brown M, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62(4):563–568. doi: 10.1212/01.WNL.0000110312.36809.7F
   PubMed Web of Science ®Google Scholar
• Dodick DW, Martin V. Triptans and CNS side effects: pharmacokinetic and metabolic mechanism. Cephalalgia. 2004;24(6):417–424. doi: 10.1111/j.1468-2982.2004.00694.x
   PubMed Web of Science ®Google Scholar
• Ferrari MIW, Färkkilä M, Reuter U. Acute treatment of migraine with the selective 5-HT 1F receptor agonist lasmiditan – a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170–1178. doi: 10.1177/0333102410375512
   PubMed Web of Science ®Google Scholar
• Nelson DL, Phebus LA, Johnson KIW. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30:1159–1169. doi: 10.1177/0333102410370873
   PubMed Web of Science ®Google Scholar
• on behalf of the COL MIG-301 Study Group, Kuca B, Silberstein SD, et al. Lasmiditan is an effective acute treatment for migraine. A phase 3 randomized study. Neurology. 2018;91(24):e2222–e2232.
   PubMed Web of Science ®Google Scholar
• Farkkila M, Diener H-C, Lainez JM, et al. Lasmiditan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine. J Headache Pain. 2010;11(Supl 1):209.
   Google Scholar
• Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–1904. doi: 10.1093/brain/awz134
   PubMed Web of Science ®Google Scholar
• Rau JC, Navratilova E, Oyarzo J, et al. Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia. 2020;40(9):903–912. doi: 10.1177/0333102420920006
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Fritsche G, Muessig M. Drug approval package: Reyvow. lowing overuse of triptans and other headache drugs. Neurology. 2001;57(9):1694–1698. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280
   PubMed Web of Science ®Google Scholar
• Hong P, Tan T, Liu Y, et al. Gepants for abortive treatment of migraine: a network meta-analysis. Brain Behav. 2020;10(8):1701. doi: 10.1002/brb3.1701
   PubMed Web of Science ®Google Scholar
• Tourias K, Pavitt S Safety and efficacy of oral calcitonin gene-related peptide receptor antagonists for the acute treatment of migraine in the pediatric population. Presented at Presented at the American Academy of Neurology Annual Meeting; 2023 Apr 22-27; Boston, USA. p. 9.12–010
   Google Scholar
• Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001;57(9):1694–1698. doi: 10.1212/WNL.57.9.1694
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241. doi: 10.1056/NEJMoa1813049
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–1898. doi: 10.1001/jama.2019.16711
   PubMed Web of Science ®Google Scholar
• Moore E, Fraley ME, Bell IMIW. Characterization of ubrogepant: a potent and selective antagonist of the human calcitonin gene‒related peptide receptor. J Pharmacol Exp Ther. 2020;jpet:119.261065. doi: 10.1124/jpet.119.261065
   Web of Science ®Google Scholar
• Yang Y, Chen M, Sun Y, et al. Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs. 2020;34(5):463–471. doi: 10.1007/s40263-020-00715-7
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache. 2020;60(4):686–700. doi: 10.1111/head.13766
   PubMed Web of Science ®Google Scholar
• Edinoff AN, Casey CA, Colon MA, et al. Ubrogepant to treat acute migraine in adults. Neurol Int. 2021;13(1):32–45. doi: 10.3390/neurolint13010004
   PubMed Web of Science ®Google Scholar
• Pan KS, Siow A, Hay DL, et al. Antagonism of CGRP signaling by rimegepant at two receptors. Front Pharmacol. 1240;2020:11. doi:10.3389/fphar.2020.01240
   Google Scholar
• Goadsby PJ, Ailani J, Dodick DW, et al. Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): results from the PRODROME trial. Presented at the American Academy of Neurology Annual Meeting; 2023 Apr 22-27; Boston, USA. p.S47.002
   Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–745. doi: 10.1016/S0140-6736(19)31606-X
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–149. doi: 10.1056/NEJMoa1811090
   PubMed Web of Science ®Google Scholar
• Drug approval package: nurtec ODT. [cited 2021 Mar 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212728Orig1s000TOC.cfm.
   Google Scholar
• Pavlovic J, Smith T, Mullin K, et al. 10 mg nasal spray is effective for the acute treatment of migraine regardless of attack frequency: pooled results from 2 randomized, placebo-controlled clinical trials. Presented at the American Academy of Neurology Annual Meeting; 2023 Apr 22-27; Boston, USA. p. 003.
   Google Scholar
• Mathew NT, Kailasam J, Meadors L, et al. Intravenous valproate sodium (Depacon) aborts migraine rapidly: a preliminary report. Headache. 2000;40(9):720–723. doi: 10.1046/j.1526-4610.2000.00125.x
   PubMed Web of Science ®Google Scholar
• Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. Cephalalgia. 2002a;22(5):345–353. doi: 10.1046/j.1468-2982.2002.00364.x
   PubMed Web of Science ®Google Scholar
• Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004. Eur J Neurol. 2004;11(9):577–581. doi: 10.1111/j.1468-1331.2004.00867.x
   PubMed Web of Science ®Google Scholar
• Hamilton KT, Robbins MS. Migraine treatment in pregnant women presenting to acute care: a retrospective observational study. Headache. 2019;59(2):173–179. doi: 10.1111/head.13434
   PubMed Web of Science ®Google Scholar
• Ephross SA, Sinclair SM. Final results from the 16-year S umatriptan, N aratriptan, and T reximet P regnancy R egistry. Headache. 2014;54(7):1158–1172. doi: 10.1111/head.12375
   PubMed Web of Science ®Google Scholar
• Silberstein S, Young WB, Mendizabal JE, et al. Efficacy of intramuscular droperidol for migraine treatment: a dose-response study. Cephalalgia. 2001;21:271–272.
   Google Scholar
• Tanen DA, Miller S, French T, et al. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003;41(6):847–53. doi: 10.1067/mem.2003.195
   PubMed Web of Science ®Google Scholar
• Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005 Feb;64(3):463–468. doi: 10.1212/01.WNL.0000150904.28131.DD
   PubMed Web of Science ®Google Scholar
• Friedman BW, Solorzano C, Kessler BD, et al. Randomized trial comparing low- vs high-dose IV dexamethasone for patients with moderate to severe migraine. Neurology. 2023;101(14):e1448. doi: 10.1212/WNL.0000000000207648
   PubMed Web of Science ®Google Scholar
• Baker T, Croop R, Kamen L, et al. Human milk and plasma pharmacokinetics of single-dose rimegepant 75 mg in healthy lactating women. Breastfeeding Med Mar. 2022;17(3):277–282. doi: 10.1089/bfm.2021.0250
   PubMed Web of Science ®Google Scholar